About casirivimab + imdevimab
Monoclonal antibody combination
Used for
- Treatment of COVID-19 in eligible patients, depending on circulating variants and local guidance.
- Prevention of COVID-19 after exposure or before exposure in some settings.
Usual adult dose
COVID-19 treatment: 600 mg casirivimab plus 600 mg imdevimab once. Prevention regimens vary by indication and local guidance.
Usual dose in children
For eligible children aged 12 years or older and weighing at least 40 kg, treatment dose is 600 mg of each antibody once.
Common side effects
- Infusion or injection reactions, including rash, itching, and flushing.
- Allergic reactions, sometimes severe.
- Nausea and dizziness.
- Injection-site pain or redness.
Important warnings
- Benefit may be reduced against variants resistant to these antibodies; check current local guidance.
- Serious hypersensitivity and infusion reactions can occur.
- Not a substitute for COVID-19 vaccination.
- Use and eligibility depend on current authorization and COVID-19 risk.
Pregnancy
Human pregnancy data are limited. Use only when potential benefit justifies possible risk.
Breastfeeding
It is not known whether these antibodies enter breast milk; consider treatment benefits and breastfeeding benefits.
Interactions
- No clinically important interactions are expected; formal interaction studies are limited.
- COVID-19 vaccination may need to be timed around treatment; follow current guidance.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.